Izotropic Corp

Izotropic Corp has a highly leveraged capital structure, with total liabilities of CAD 4,078,630 and total equity of CAD -3,846,250, resulting in a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.04 and a debt-to-equity ratio of -0.53, indicating that liabilities significantly outweigh equity. Despite a small amount of cash and equivalents (CAD 28,750), the company's operating cash flow is negative at CAD -593,570, and free cash flow is only CAD 14,990, suggesting limited ability to fund operations or reduce debt.

Profitability is severely constrained, with a net income of CAD 170 and an operating income of CAD 90,420. The return on assets is a minimal 0.07%, and return on equity is effectively zero, indicating that the company is not generating returns that justify its asset base or equity investment. These metrics fall well below the industry median for profitability and returns, which typically require higher margins and asset efficiency to sustain operations.

The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, where demand can be sensitive to regulatory changes and technological shifts.

Looking ahead, the company is expected to see a modest increase in revenue, with analyst estimates projecting CAD 5,000,000 for the current fiscal year. However, this represents a relatively small growth rate compared to historical performance, and the company's ability to meet these projections is constrained by its weak liquidity and high debt load. The operating cash flow remains a concern, as it is insufficient to cover debt obligations or support meaningful reinvestment.

The company faces several risk factors, including liquidity constraints and the potential for dilution if it issues additional shares to raise capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net worth and high debt-to-equity ratio suggest that the company may need to seek additional financing in the near term. The risk of dilution is currently low, but the company's financial position could deteriorate if it is unable to improve its cash flow or secure new funding.

Recent filings and transcripts indicate that the company is actively seeking to improve its financial position through cost-cutting measures and potential partnerships. However, no significant new product launches or major contracts have been disclosed in the latest available data. The company's management has acknowledged the need for strategic adjustments to address its liquidity challenges and improve long-term sustainability.

Operating income −0,1% YoY; Net income +46,2% YoY.

• ▍Operating income −0,1% YoY
• ▍Net income +46,2% YoY
• ▍Free cash flow +46,4% YoY

Operating income −88,3% YoY; Net income −128,2% YoY.

• ▍Operating income −88,3% YoY
• ▍Net income −128,2% YoY
• ▍Free cash flow −136,3% YoY